The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A new study showed that semaglutide may help with alcohol use disorder Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared in Billboard and Reader's Digest.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It found that semaglutide, the substance in Ozempic and the weight loss ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes. In the intervening years, a lucrative industry of telehealth ...

The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro ...

Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less ...

Feb. 13, 2025 – For years, some people taking the drug semaglutide to treat diabetes or obesity have reported not only eating less, but drinking less alcohol. The reports have prompted many to ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol. A study published in JAMA Psychiatry enrolled ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...